[Chemotherapy and thymostimulin in the treatment of advanced-stage breast neoplasms].

In this study, we have evaluated certain haematologic and immunologic parameters in two advanced disease patient groups treated with chemotherapy (CMF schedule)+thymostimulin or chemotherapy alone, respectively. Statistical analysis of the data does not reveal any significant difference between the two patient groups. In our opinion, however, the administration of thymic hormone seems to protect the marrow crasis and, as a consequence, to obtain a lower incidence of side effects and respect of chemotherapeutic schedule.